Centaur
+37%
est. 2Y upside i
Quality-first data labeling for model evaluation and training
Rank
#1240
Sector
Healthcare IT
Est. Liquidity
~4Y
Data Quality
Data: MediumCentaur offers a high-risk, high-reward equity opportunity with an expected 2-year upside of ~37% from common stock.
Last updated: July 3, 2026
Strong growth and partnership with Protege for multimodal annotation drive multiple expansion to 12x. If IPO window opens, common stock gains 174% after 20% dilution.
Revenue grows to $13.9M, exit multiple converges to 8x. After preference and 20% dilution, common stock returns 50%.
Increased competition from Scale AI and Big Tech compresses multiple to 5x. Preference overhang and dilution lead to a 43% loss on common stock.
Preference Stack Risk
severeFunding Intensity
4375%Total funding of $35M is 44% of estimated $80M valuation, giving preferred stockholders a large liquidation preference ahead of common.
Dilution Risk
highWith no profitability and high growth, additional funding rounds are likely within 2 years, diluting common equity by an estimated 20%.
Secondary Liquidity
noneNo secondary market activity detected; employees may face limited liquidity until an exit event.
Questions to Ask at the Interview
Strategic questions based on Centaur's data — designed to show you've done your homework.
- 1
“How do you plan to defend against Scale AI's expansion into healthcare?”
- 2
“What is your path to profitability given current burn rate and revenue growth?”
- 3
“What is the current 409A valuation and how frequently is it updated?”
Community
Valuation Sentiment
Our model estimates +37% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.